Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03901573 · ClinicalTrials.gov registry record · Phase 1
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
A Phase 1 study, sponsored by NeoImmuneTech.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT03901573 is a Phase 1 study that was terminated before completion, run by NeoImmuneTech. The registered enrollment target is 31 participants.
The verdict
NCT03901573, a Phase 1 study, was terminated before completion, sponsored by NeoImmuneTech.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)
Interventions
- DRUG NT-I7
- DRUG atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-12-26 |
| Est. Completion | 2023-08-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03901573
The ClinicalTrials.gov registry entry for NCT03901573 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NeoImmuneTech, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NT-I7 is the first listed.
NCT03901573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03901573 about?
NCT03901573 is a clinical study titled "High-Risk Skin Cancers With Atezolizumab Plus NT-I7". The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)
What is the current status of trial NCT03901573?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2019-12-26. Estimated completion is 2023-08-15.
What interventions are being tested in trial NCT03901573?
The interventions under investigation include: NT-I7 (DRUG), atezolizumab (DRUG).
Who is sponsoring clinical trial NCT03901573?
This trial is sponsored by NeoImmuneTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.